Cargando…
Development and validation of the patient roles and responsibilities scale in cancer patients
PURPOSE: The Patient Roles and Responsibilities Scale (PRRS) was developed to enable a broader evaluation of the impact of cancer and cancer treatment, measuring ‘real world’ roles and responsibilities such as caring for others and financial and employment responsibilities. Here, we report the devel...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208586/ https://www.ncbi.nlm.nih.gov/pubmed/30051259 http://dx.doi.org/10.1007/s11136-018-1940-2 |
_version_ | 1783366730283745280 |
---|---|
author | Shilling, Valerie Starkings, Rachel Jenkins, Valerie Cella, David Fallowfield, Lesley |
author_facet | Shilling, Valerie Starkings, Rachel Jenkins, Valerie Cella, David Fallowfield, Lesley |
author_sort | Shilling, Valerie |
collection | PubMed |
description | PURPOSE: The Patient Roles and Responsibilities Scale (PRRS) was developed to enable a broader evaluation of the impact of cancer and cancer treatment, measuring ‘real world’ roles and responsibilities such as caring for others and financial and employment responsibilities. Here, we report the development and initial validation. METHODS: The 29-item PRRS was developed from the thematic analysis of two interview studies with cancer patients and caregivers. In the evaluation study, participants completed the PRRS alongside the Social Difficulties Inventory (SDI), the main criterion measure for concurrent validity, and the Functional Assessment of Cancer Therapy - General and WHO Quality of Life-BREF (WHOQOL-BREF) for additional convergent validity data. Questionnaires were completed at baseline, 7-days (PRRS only) and 2 months. Demographic data and patient characteristics were collected at baseline. RESULTS: One hundred and thirty-five patients with stage III/IV breast, lung or gynaecological cancer or melanoma completed the PRRS at least once. Five items performed poorly and were removed from the scale. The final 16 core items selected comprised 3 dimensions: family well-being, responsibilities and social life, and financial well-being, identified in principal component analysis, accounting for 61.5% of total variance. Missing data (0.6%) and floor/ceiling effects were low (0%/1.5%). Cronbach’s alpha was 0.9 for the PRRS-16; 0.79–0.87 for the subscales. PRRS showed good test–retest reliability (ICC-0.86), sensitivity to change and the predicted pattern of correlation with validation measures r = |0.65–0.77|. The standalone 7-item jobs and careers subscale requires further validation. CONCLUSIONS: Initial evaluation shows that the PRRS is psychometrically robust with potential to inform the evaluation of new treatments in clinical trials and real-world studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11136-018-1940-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6208586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-62085862018-11-09 Development and validation of the patient roles and responsibilities scale in cancer patients Shilling, Valerie Starkings, Rachel Jenkins, Valerie Cella, David Fallowfield, Lesley Qual Life Res Article PURPOSE: The Patient Roles and Responsibilities Scale (PRRS) was developed to enable a broader evaluation of the impact of cancer and cancer treatment, measuring ‘real world’ roles and responsibilities such as caring for others and financial and employment responsibilities. Here, we report the development and initial validation. METHODS: The 29-item PRRS was developed from the thematic analysis of two interview studies with cancer patients and caregivers. In the evaluation study, participants completed the PRRS alongside the Social Difficulties Inventory (SDI), the main criterion measure for concurrent validity, and the Functional Assessment of Cancer Therapy - General and WHO Quality of Life-BREF (WHOQOL-BREF) for additional convergent validity data. Questionnaires were completed at baseline, 7-days (PRRS only) and 2 months. Demographic data and patient characteristics were collected at baseline. RESULTS: One hundred and thirty-five patients with stage III/IV breast, lung or gynaecological cancer or melanoma completed the PRRS at least once. Five items performed poorly and were removed from the scale. The final 16 core items selected comprised 3 dimensions: family well-being, responsibilities and social life, and financial well-being, identified in principal component analysis, accounting for 61.5% of total variance. Missing data (0.6%) and floor/ceiling effects were low (0%/1.5%). Cronbach’s alpha was 0.9 for the PRRS-16; 0.79–0.87 for the subscales. PRRS showed good test–retest reliability (ICC-0.86), sensitivity to change and the predicted pattern of correlation with validation measures r = |0.65–0.77|. The standalone 7-item jobs and careers subscale requires further validation. CONCLUSIONS: Initial evaluation shows that the PRRS is psychometrically robust with potential to inform the evaluation of new treatments in clinical trials and real-world studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11136-018-1940-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-07-26 2018 /pmc/articles/PMC6208586/ /pubmed/30051259 http://dx.doi.org/10.1007/s11136-018-1940-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Article Shilling, Valerie Starkings, Rachel Jenkins, Valerie Cella, David Fallowfield, Lesley Development and validation of the patient roles and responsibilities scale in cancer patients |
title | Development and validation of the patient roles and responsibilities scale in cancer patients |
title_full | Development and validation of the patient roles and responsibilities scale in cancer patients |
title_fullStr | Development and validation of the patient roles and responsibilities scale in cancer patients |
title_full_unstemmed | Development and validation of the patient roles and responsibilities scale in cancer patients |
title_short | Development and validation of the patient roles and responsibilities scale in cancer patients |
title_sort | development and validation of the patient roles and responsibilities scale in cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208586/ https://www.ncbi.nlm.nih.gov/pubmed/30051259 http://dx.doi.org/10.1007/s11136-018-1940-2 |
work_keys_str_mv | AT shillingvalerie developmentandvalidationofthepatientrolesandresponsibilitiesscaleincancerpatients AT starkingsrachel developmentandvalidationofthepatientrolesandresponsibilitiesscaleincancerpatients AT jenkinsvalerie developmentandvalidationofthepatientrolesandresponsibilitiesscaleincancerpatients AT celladavid developmentandvalidationofthepatientrolesandresponsibilitiesscaleincancerpatients AT fallowfieldlesley developmentandvalidationofthepatientrolesandresponsibilitiesscaleincancerpatients |